FY2025 EPS Estimates for ClearPoint Neuro Lifted by B. Riley

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Stock analysts at B. Riley boosted their FY2025 earnings per share (EPS) estimates for ClearPoint Neuro in a research note issued to investors on Thursday, February 27th. B. Riley analyst K. Bauser now anticipates that the company will post earnings per share of ($0.58) for the year, up from their prior estimate of ($0.59). B. Riley has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q4 2025 earnings at ($0.15) EPS.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $8.23 million.

Separately, Lake Street Capital lifted their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st.

ClearPoint Neuro Stock Down 1.0 %

ClearPoint Neuro stock opened at $13.41 on Monday. The business has a 50-day simple moving average of $16.57 and a 200 day simple moving average of $13.93. ClearPoint Neuro has a 52 week low of $5.11 and a 52 week high of $19.22. The stock has a market cap of $370.55 million, a price-to-earnings ratio of -19.43 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLPT. R Squared Ltd purchased a new position in ClearPoint Neuro during the 4th quarter valued at about $32,000. Barclays PLC lifted its position in ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after acquiring an additional 1,109 shares in the last quarter. AlphaQuest LLC bought a new position in ClearPoint Neuro in the 4th quarter valued at approximately $80,000. Tower Research Capital LLC TRC purchased a new position in shares of ClearPoint Neuro in the 4th quarter worth $93,000. Finally, JPMorgan Chase & Co. lifted its position in ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after purchasing an additional 3,612 shares in the last quarter. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.